Abstract

CYP2D6 belongs to the cytochrome P450 superfamily of enzymes and plays an important role in the metabolism of 20–25% of clinically used drugs including antidepressants. It displays inter-individual and inter-ethnic variability in activity ranging from complete absence to excessive activity which causes adverse drug reactions and toxicity or therapy failure even at normal drug doses. This variability is due to genetic polymorphisms which form poor, intermediate, extensive or ultrarapid metaboliser phenotypes. This study aimed to determine CYP2D6 alleles and their frequencies in the United Arab Emirates (UAE) local population. CYP2D6 alleles and genotypes were determined by direct DNA sequencing in 151 Emiratis with the majority being psychiatric patients on antidepressants. Several new alleles have been identified and in total we identified seventeen alleles and 49 genotypes. CYP2D6*1 (wild type) and CYP2D6*2 alleles (extensive metaboliser phenotype) were found with frequencies of 39.1% and 12.2%, respectively. CYP2D6*41 (intermediate metaboliser) occurred in 15.2%. Homozygous CYP2D6*4 allele (poor metaboliser) was found with a frequency of 2% while homozygous and heterozygous CYP2D6*4 occurred with a frequency of 9%. CYP2D6*2xn, caused by gene duplication (ultrarapid metaboliser) had a frequency of 4.3%. CYP2D6 gene duplication/multiduplication occurred in 16% but only 11.2% who carried more than 2 active functional alleles were considered ultrarapid metabolisers. CYP2D6 gene deletion in one copy occurred in 7.5% of the study group. In conclusion, CYP2D6 gene locus is heterogeneous in the UAE national population and no significant differences have been identified between the psychiatric patients and controls.

Highlights

  • Interethnic variation in the capacity to metabolize drugs is mainly due to genetic constitution [1]

  • The best characterized genetically determined variations in antidepressant drug metabolism are those associated with the polymorphic N-acetyltransferase, NAT2, and two polymorphic cytochrome P450s involved with oxidation reactions, CYP2D6 and CYP2C19, all of which show marked interethnic differences in catalytic activity and allele distribution [3]

  • The impact of CYP2D6 polymorphisms on the clinical outcome of psychoactive drugs has been extensively described in the literature [12]

Read more

Summary

Introduction

Interethnic variation in the capacity to metabolize drugs is mainly due to genetic constitution [1]. The CYP2D6 locus is highly polymorphic and currently more than 120 variant CYP2D6 alleles have been described (www.cypalleles.ki.se/cyp2d6.htm) These alleles can be divided into; 1) alleles resulting in no functional product (poor metabolizers, PMs); 2) alleles causing a reduced rate of metabolism (intermediate metabolizers, IMs); 3) alleles causing ultrarapid metabolism (ultra-rapid metabolizers, UMs); and 4) alleles with no important functional consequences (extensive metabolizers, EMs) [7] Given the relatively wide spread use of CYP2D6-metabolised medications, including antidepressants, and limited availability of data regarding the alleles and genotypes in Emiratis, this study was undertaken to determine CYP2D6 alleles and their frequencies, using direct DNA sequencing of the full coding regions and large parts of the intronic sequences, in this population

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call